What is the treatment for a patient who is hepatitis B surface antigen (HBsAg) positive?

Management of Hepatitis B Surface Antigen Positive Patients

Patients who are hepatitis B surface antigen (HBsAg) positive require antiviral therapy with high-potency nucleos(t)ide analogues (NAs) with high barrier to resistance, specifically entecavir, tenofovir disoproxil fumarate (TDF), or tenofovir alafenamide (TAF) as first-line treatments. 1

Treatment Indications

Treatment decisions for HBsAg-positive patients should be based on:

• HBV DNA levels:

  • Treatment recommended if HBV DNA >2000 IU/mL (EASL) 2
  • Treatment recommended if HBV DNA ≥20,000 IU/mL (AASLD) 1

• ALT levels:

  • Treatment recommended if ALT >ULN (EASL) 2
  • Treatment recommended if ALT >2× ULN (AASLD) 1

• Liver disease severity:

  • All patients with compensated or decompensated cirrhosis with any detectable HBV DNA should be treated regardless of ALT levels 2, 1
  • Patients with at least moderate liver necroinflammation or fibrosis should be treated 1

First-Line Treatment Options

Antiviral Agent	Dosage
Entecavir	0.5 mg daily
Tenofovir disoproxil fumarate (TDF)	300 mg daily
Tenofovir alafenamide (TAF)	25 mg daily

1

Important Considerations

• Avoid lamivudine due to high risk of resistance development 2
• Monitor hepatitis B viral load with PCR monthly during treatment and every 3 months thereafter 2
• Continue treatment long-term as discontinuation can lead to viral reactivation 2
• Monitor renal function every 6-12 months, especially in patients receiving tenofovir 1
• Perform regular liver assessments including ALT/AST levels every 3-6 months 1

Special Populations

Immunosuppressed Patients

• HBsAg-positive patients receiving immunosuppressive therapy require prophylactic antiviral therapy 2
• Treatment should continue for at least 6 months after discontinuation of immunosuppressive therapy (at least 12 months for B cell–depleting agents) 2
• Use high genetic barrier drugs (entecavir, TDF, or TAF) to prevent reactivation 1

Pregnant Women

• TDF recommended for pregnant women with high HBV DNA levels (>200,000 IU/mL) starting at 24-28 weeks of gestation 2, 1

HIV Co-infection

• Include tenofovir in the antiretroviral regimen 1
• Avoid lamivudine monotherapy 1, 3

Treatment Goals and Monitoring

The primary goals of therapy are:

1. Suppression of HBV DNA to undetectable levels
2. ALT normalization
3. Improvement in liver histology
4. Prevention of cirrhosis, hepatocellular carcinoma, and liver-related death

1

Regular monitoring should include:

• HBV DNA levels every 3-6 months
• ALT/AST levels every 3-6 months
• HBeAg/anti-HBe status every 6-12 months (in HBeAg-positive patients)
• Renal function every 6-12 months
• Non-invasive fibrosis assessment annually

1

Common Pitfalls to Avoid

• Discontinuing treatment prematurely: Stopping therapy can lead to severe reactivation of hepatitis B
• Inadequate monitoring: Failure to monitor viral load, liver function, and renal function regularly
• Using lamivudine as monotherapy: High risk of resistance development
• Overlooking HBV screening before immunosuppressive therapy: All patients should be screened for HBsAg and anti-HBc before starting immunosuppressive therapy 2
• Failing to identify patients at risk for HCC: Patients with cirrhosis or family history of HCC require closer monitoring 1, 4

By following these guidelines, clinicians can effectively manage HBsAg-positive patients to prevent disease progression, reduce complications, and improve long-term outcomes.